Literature DB >> 33717725

Discontinuation of Intermittent Hemodialysis in HIV-Associated Nephropathy Following Initiation of Antiretroviral Therapy.

Mohamedanwar Ghandour1, Hammam Shereef2, Omeralfaroug Adam3, Yahya Osman-Malik4, Zeenat Bhat1.   

Abstract

Human immunodeficiency virus (HIV) infection occurs due to the HIV virus. It results in an immunodeficient state and multi-organ system infections and malignancy known as AIDS. HIV-associated nephropathy (HIVAN) is the most common HIV kidney involvement and may present as acute kidney injury (AKI), as well as chronic kidney disease (CKD). HIVAN is a collapsing form of focal segmental glomerulosclerosis (FSGS). HIVAN treatment options include antiretroviral therapy (ART), steroids, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB), and hemodialysis (HD). We herein describe the case of a 40-year-old patient with an established diagnosis of HIVAN who has had partial recovery of end-stage renal failure following the initiation of ART.
Copyright © 2021, Ghandour et al.

Entities:  

Keywords:  acquired immune deficiency syndrome (aids); antiretroviral therapy (art); hiv-associated nephropathy

Year:  2021        PMID: 33717725      PMCID: PMC7939417          DOI: 10.7759/cureus.13181

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  15 in total

1.  Stable improvement of renal function after initiation of highly active anti-retroviral therapy in patients with HIV-1-associated nephropathy.

Authors:  Michiel G H Betjes; Dominique W M Verhagen
Journal:  Nephrol Dial Transplant       Date:  2002-10       Impact factor: 5.992

2.  Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study.

Authors:  A Laurinavicius; S Hurwitz; H G Rennke
Journal:  Kidney Int       Date:  1999-12       Impact factor: 10.612

3.  Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression.

Authors:  L A Bruggeman; S Dikman; C Meng; S E Quaggin; T M Coffman; P E Klotman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

4.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.

Authors:  Jeffrey B Kopp; Michael W Smith; George W Nelson; Randall C Johnson; Barry I Freedman; Donald W Bowden; Taras Oleksyk; Louise M McKenzie; Hiroshi Kajiyama; Tejinder S Ahuja; Jeffrey S Berns; William Briggs; Monique E Cho; Richard A Dart; Paul L Kimmel; Stephen M Korbet; Donna M Michel; Michele H Mokrzycki; Jeffrey R Schelling; Eric Simon; Howard Trachtman; David Vlahov; Cheryl A Winkler
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

Review 5.  HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment.

Authors:  Avi Z Rosenberg; Saraladevi Naicker; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2015-02-17       Impact factor: 28.314

Review 6.  Kidney Diseases Associated with Human Immunodeficiency Virus Infection.

Authors:  Scott D Cohen; Jeffrey B Kopp; Paul L Kimmel
Journal:  N Engl J Med       Date:  2017-12-14       Impact factor: 91.245

7.  Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy.

Authors:  B I Freedman; J M Soucie; S M Stone; S Pegram
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

Review 8.  HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection.

Authors:  J A Winston; M E Klotman; P E Klotman
Journal:  Kidney Int       Date:  1999-03       Impact factor: 10.612

9.  Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome.

Authors:  T K Rao; E J Filippone; A D Nicastri; S H Landesman; E Frank; C K Chen; E A Friedman
Journal:  N Engl J Med       Date:  1984-03-15       Impact factor: 91.245

10.  Renal disease in patients with AIDS: a clinicopathologic study.

Authors:  M H Gardenswartz; C W Lerner; G R Seligson; P M Zabetakis; H Rotterdam; M L Tapper; M F Michelis; M S Bruno
Journal:  Clin Nephrol       Date:  1984-04       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.